This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

TranS1 Inc. Announces Two Clinical Papers Accepted For Publication, Updates First Quarter 2011 Guidance

WILMINGTON, N.C., March 21, 2011 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region, today announced that two noteworthy clinical papers have been accepted for publication in peer-reviewed journals. In addition, TranS1 updated its revenue guidance for the first quarter of 2011. 

Clinical Publication Update

TranS1 recently received notification that two clinical papers highlighting the efficacy and safety of its AxiaLIF spinal fusion procedure have been approved for publication. The first paper reviews efficacy data from a four site, 156 patient study with two-year follow up and demonstrates a 94% fusion rate. This paper has been accepted for publication in SPINE.   The second paper is a 9,152 patient retrospective safety study that shows a 1.3% complication rate. This paper has been accepted for publication in the SAS Journal.

"The publication of significant clinical data supporting the use of our AxiaLIF approach is critical to our reimbursement strategy," commented Ken Reali, President and Chief Executive Officer of TranS1 Inc. "We believe that these papers will be important as we pursue additional payor coverage decisions for our Category 3 CPT code and seek to gain society support for the graduation of the current Category 3 code to a Category 1 code."

TranS1 Outlook

For the first quarter ending March 31, 2011, the company expects total revenues in the range of $4.8 - $5.2 million. Previously, the company had expected revenues to be in the range of $5.0 - $6.0 million.

"Our sales for the quarter will be at the low end of our previously anticipated range as our business continues to be adversely affected by general spine market conditions and ongoing AxiaLIF physician reimbursement pressures," commented Ken Reali, President and Chief Executive Officer of TranS1 Inc.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs